birdflustocks.com
Home
Facts
Idea
Stocks
Brokers
admin
birdflustocks.com
»
admin
admin
CureVac/GSK: Start of combined phase 1/2 study for avian influenza (H5N1) mRNA vaccine
By
admin
|
24
Apr, 24
|
CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 study
By
admin
|
4
Apr, 24
|
SAB Biotherapeutics: Partnership with Naval Medical Research Center for SAB-176 study
By
admin
|
25
Mar, 24
|
SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a
Vir Biotechnology/GSK: Antibody cooperation ended
By
admin
|
23
Feb, 24
|
The partners have ended their collaboration on anti-influenza antibodies, freeing
BioNTech/CureVac: German court voids CureVac patent after BioNTech challenge, stock drops 41%
By
admin
|
19
Dec, 23
|
https://www.maucherjenkins.com/commentary/first-instance-declares-german-curevac-patent-on-mrna-vaccine-against-covid-19-invalid
BioNTech/Moderna: EPO revokes Moderna patent in vaccine dispute with BioNTech
By
admin
|
21
Nov, 23
|
GSK: GSK sells Haleon shares to sharpen its focus on vaccines and infectious diseases
By
admin
|
7
Oct, 23
|
GSK raises $1.1 billion from Haleon stake sale https://www.reuters.com/markets/deals/gsk-raises-886-mln-pounds-haleon-stake-sale-2023-10-06/
BioNTech/Pfizer: Pfizer and BioNTech resolve mRNA patent lawsuit filed by Promosome
By
admin
|
7
Oct, 23
|
No financial terms were disclosed. https://www.reuters.com/legal/pfizer-resolves-promosome-patent-lawsuit-over-covid-19-vaccine-2023-10-05/
Moderna: mRNA-1010 Seasonal Influenza Vaccine phase 3 study successfully completed
By
admin
|
13
Sep, 23
|
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-scale-down-manufacturing-covid-vaccine-2023-09-13/
CureVac/GSK: mRNA seasonal influenza vaccine development advances to phase 2 study
By
admin
|
12
Sep, 23
|
Previous
1
2
3
4
5
Next